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Abstract 77 
Digital health technology, especially digital and health applications (“apps”), have been 78 
developing rapidly to help people manage their diabetes. Numerous health-related apps 79 
provided on smartphones and other wireless devices are available to support people with 80 
diabetes with either lifestyle interventions or medication adjustments in response to glucose 81 
monitoring data. However, regulations and guidelines have not caught up with the burgeoning 82 
field to standardize how mobile health apps are reviewed and monitored for patient safety and 83 
clinical validity. The available evidence on the safety and effectiveness of mobile health apps, 84 
especially for diabetes, remains limited. The European Association for the Study of Diabetes 85 
and the American Diabetes Association have therefore conducted a joint review of the current 86 
landscape of available diabetes digital health technology (only standalone diabetes apps, as 87 
opposed to those that are integral to a regulated medical device, such as insulin pumps, CGM 88 
systems, and closed loop control systems) and practices of regulatory authorities and 89 
organizations. We found that across the United States and Europe, mobile apps intended to 90 
manage health and wellness are largely unregulated unless they meet the definition of medical 91 
devices for therapeutic and/or diagnostic purposes. International organizations, including the 92 
International Medical Device Regulators Forum and World Health Organization, have made 93 
strides in classifying different types of digital health technology and fitting digital health 94 
technology within the space of medical devices. As the diabetes digital health field continues to 95 
develop and become more integrated into everyday life, we wish to ensure that it is based on 96 
the best evidence for safety and efficacy. As a result, we bring to light several issues that the 97 
diabetes community, including regulatory authorities, policymakers, professional organizations, 98 
researchers, people with diabetes, and health care professionals (HCPs), needs to address to 99 
ensure that diabetes health technology can meet its full potential. These issues range from 100 
inadequate evidence on app accuracy and clinical validity to lack of training provision, poor 101 
interoperability and standardization, and insufficient security of data. We conclude with a series 102 
of recommended actions to resolve some of these shortcomings.  103 
  104 
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Introduction 105 
Coincident with the diabetes pandemic of the last three decades has been a revolution in digital 106 
and wireless technology.1 These technological advances have been harnessed to support 107 
lifestyle and pharmacological interventions, as well as medical devices (blood glucose meters, 108 
continuous glucose monitoring (CGM) devices, insulin pumps, and smart pens).2,3,4,5 At the 109 
forefront is the burgeoning field of digital health technology for people with or at risk for 110 
diabetes, which has proliferated and begun to permeate clinical care, research, and health 111 
product development.6  112 
 113 
This position statement focuses on digital health apps. Digital health, also known as mobile 114 
health (“mHealth”), is defined by the World Health Organization (WHO) Global Observatory for 115 
eHealth (GOe) as “medical and public health practice supported by mobile devices, such as 116 
mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other 117 
wireless or stationary devices.”7 Digital health apps can be generally broken down into three 118 
categories: those used for tracking wellness, those that function as standalone medical devices 119 
(e.g., for titrating insulin), and those that display, download, and/or use data from medical 120 
devices that diagnose, prevent, monitor, or treat a condition (e.g., blood glucose monitoring 121 
[BGM], continuous glucose monitoring [CGM], insulin pump, or closed loop control system [also 122 
known as Automated Insulin Delivery system]).8 Among almost half a million health-related apps 123 
available for wireless devices (usually smartphones),9,10 apps designed to help manage 124 
diabetes are among those most commonly available.11 These are intended to improve health 125 
outcomes and quality of life by coaching people with diabetes, supporting healthy nutrition and 126 
weight control, encouraging glucose monitoring and remote monitoring, assisting with the 127 
interpretation of results, maintaining lifestyle modifications, guiding medication dosing and, 128 
ultimately, reducing complications.12 Due to the vastness of the field of digital health apps, this 129 
position statement will go into discussion of only standalone apps that are not integral to a 130 
regulated medical device. Examples of what is out of scope of this position statement include 131 
insulin pumps and closed loop control systems. 132 
 133 
Table 1 lists examples of digital health apps used for managing diabetes according to their 134 
intended purpose. It is important to note that many of the aforementioned apps have more than 135 
one feature, and not all are solely for managing diabetes. Earlier in 2019, Kebede and Pischke 136 
conducted a study that aimed to identify the most popular diabetes apps via a web-based 137 
survey among the diabetes social media community.13  138 
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Table 1: Types of Digital Health Apps Used for Managing Diabetes 139 
Category Name Description/Definition Examples 
(i) Nutrition apps • Offer databases where 
users can look up 
carbohydrate, fat, protein and 
calorie content; 
• Support meal planning and 
insulin dose adjustment.14 
Carbs and Cals 
CarbControl 
Foodily 
Healthy 
Low Carb Program 
(ii) Physical activity apps Allow users to track their 
activity, count calories, and 
set goals for exercise and 
weight management.15 
My Fitness Pal 
Nike + Running 
Track 3 
(iii) Glucose monitoring apps • Log glucose data, typically 
from an external device that 
measures glucose (e.g., 
BGM, CGM); 
• Graphically display glucose 
levels to assist the patient 
and health care professionals 
(HCPs) with management of 
glucose control. 
Dexcom Share 
Diabetic 
Diabetes Companion 
Diabetes in Check 
Glooko Mobile App  
Tidepool Mobile 
(iv) Insulin titration apps An extension of (iii) that also 
integrate bolus calculators 
with traditional blood glucose 
meters to help people with 
diabetes calculate their basal, 
prandial, and correction 
insulin doses.14 
FDA-cleared apps: WellDoc 
BlueStar,16 Voluntis Insulia, 
Sanofi MyDose Coach, 
Glooko Mobile Insulin Dosing 
System, Amalgam iSage 
Rx,17 and Hygieia d-Nav 
Insulin Guidance System18 
(v) Insulin delivery apps • For insulin pumps and smart 
pens to collect and display 
data; includes bolus 
calculators, data 
Companion Medical InPen 
connects to its smartphone 
app via Bluetooth® to keep 
track of insulin data.20  
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downloaders, and firmware 
update apps.19 
• Such apps also provide 
decision support. 
Dexcom Clarity sends weekly 
summaries and pattern 
identification.21  
Medtronic’s Sugar IQ 
integrates BGM and insulin 
dosing analysis in close to 
real time.22 
(vi) Closed loop control 
systems (also known as 
artificial pancreas systems, 
automated insulin delivery, or 
autonomous system for 
glycemic control) 
Consists of a CGM, insulin 
infusion pump, and a 
computer-controlled algorithm 
(e.g., on a smartphone app) 
to allow communication 
between the CGM and insulin 
pump on the patient.23  
Medtronic’s MiniMed 
670G/Guardian Sensor 3 is 
the first FDA-approved hybrid 
closed loop that automates 
basil insulin delivery (still 
requires meal boluses).  
Medtronic’s MiniMed 
640G/Enlite Enhanced, which 
provides predictive low 
glucose management, is 
available in Europe.24  
 140 
Diabetes apps have enormous potential, given that more than 2.7 billion individuals in the world 141 
use smartphones25 and about 0.5 billion people already use mobile apps for diet, physical 142 
activity, and chronic disease management.26 Small-scale studies show promising results of 143 
digital programs targeting glucose control, medication adherence, weight loss, and quality of 144 
life.27,28,29,30 However, longer-term clinical evidence is needed to more accurately assess the 145 
effectiveness of diabetes digital and health apps. Currently, many apps are “stand-alone”; 146 
however, there is an increasing trend towards integration and continued automation (both in 147 
data collection and algorithm-based response). As this trend gains momentum, the landscape of 148 
apps is likely to be transformed toward greater integration.  149 
  150 
The market-driven explosion of health apps has been facilitated by current systems of 151 
regulation. However, not every app is useful or good. Our intent is not to slow growth, but rather 152 
to make a realistic assessment of what is safe and truly beneficial for people with diabetes. 153 
There are very few data on long-term benefits, and even high quality short-term data are 154 
limited.31 While apps may benefit those with the technical, literacy, and numeracy skills to 155 
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interact with them, many people with diabetes (even in high-income countries) still lack access 156 
to health care and medications (including insulin) required to sustain life, which may represent 157 
more pressing problems to address. 158 
 159 
The Diabetes Technology Working Group of the ADA and the EASD aims to complement 160 
already-published reviews, position statements, and guidelines on digital health 161 
applications32,33,34,35 by reviewing their benefits and risks while providing approaches to handle 162 
the challenges they pose. In the following discussion of this article, we cover only standalone 163 
diabetes apps, as opposed to those that are integral to a regulated medical device (e.g., insulin 164 
pump, CGM system, Automated Insulin Delivery [AID] systems). Other topics not covered here 165 
that warrant future attention are: apps specific to gathering clinical evidence, and apps that 166 
support general electronic medical record (EMR) systems.  167 
 168 
The role of regulators  169 
While most stakeholders in Europe and North America have a general understanding of the 170 
approval and regulatory processes governing pharmaceuticals and medical devices, our 171 
experience is that levels of awareness of these issues in relation to digital apps are lower. We 172 
believe it is important for people with diabetes, as well as health care professionals (HCPs), to 173 
understand aspects of diabetes app regulation.  174 
 175 
a) European Medicines Agency (EMA) 176 
The European Commission has recognized the growing digital health market. In 2012, it 177 
released guidance (updated in 2016) on the qualification and classification of standalone 178 
software used in the health care setting as a medical device.36 Under this guidance, mobile 179 
apps are considered medical devices if they are used “specifically for diagnostic and/or 180 
therapeutic purposes,” including the diagnosis, prevention, monitoring, treatment, or alleviation 181 
of disease.36 In 2014, the Communication on Digital Transformation of Health and Care in the 182 
Digital Single Market was published, listing three priorities:  183 
(i) Enable citizens to access their health data across the EU;  184 
(ii) Allow researchers and other professionals to pool health data across the EU to 185 
advance research and personalized health; and  186 
(iii) Use digital tools to empower people with diabetes to look after their health, prevent 187 
diseases, and enable feedback and interaction between users and HCPs.37  188 
 189 
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While the European authorities and Food and Drug Administration (FDA) share the broad 190 
principles of regulating both traditional health products and software, there are substantial 191 
differences in the organizational structure of medical product and software registration. The 192 
European Medicines Agency (EMA) and the FDA are each responsible for pharmaceutical 193 
regulation, but only the FDA regulates both pharmaceuticals and medical devices. In the 194 
European Union (EU), no single agency, but the European Commission, is responsible for 195 
regulation of medical devices; each individual country retains primary responsibility for 196 
organizing and delivering health services and medical care. As a result, EU member states 197 
maintain their own national pharmaceutical regulatory authorities, with the European 198 
Commission serving to complement national policies and ensure health protection according to 199 
EU policies (e.g. the new Medical Device Regulation [MDR]).38 Instead, these responsibilities 200 
are retained by individual member states, which delegate to accredited notified bodies 201 
responsibilities for implementing these regulations. These entities are accredited by the EU to 202 
assess whether a product meets the standards set by the EU Medical Devices Directive (MDD), 203 
and their decision is valid across all member states. Assessments are based on evidence of 204 
safety and performance (in contrast, the FDA may also require clinical effectiveness data, 205 
especially for “high risk devices” (see classification of medical products)).39 If these standards 206 
are met, then a manufacturer is authorized to market the product throughout the EU and label it 207 
with the Conformité Européenne (CE) Mark.40  208 
 209 
In general, the process of obtaining a CE Mark in the EU in the past has been a lower hurdle 210 
than obtaining device approval or clearance by the FDA.41 This difference in the US and EU is 211 
likely to narrow with the implementation of the European Union Medical Device Regulation 212 
(MDR), which repeals the existing directives on medical devices. The regulation was published 213 
on May 5, 2017 and allows a transition time of three years before coming into force on May 25, 214 
2020. Currently approved medical devices will have time until May 26, 2020 to meet the new 215 
MDR requirements. Among the provisions in this set of regulations are the strengthening of 216 
post-market surveillance, establishment of a comprehensive EU database on medical devices, 217 
stricter control for high-risk devices before launch in the marketplace, and a new risk 218 
classification system for in vitro diagnostic medical devices in line with international guidance.42 219 
 220 
The guidelines in individual countries align with those issued by the European Commission. For 221 
example, Sweden’s Läkemedelsverket Medical Products Agency classifies medical software as 222 
a medical device if its stated purpose complies with the definition in Article 1 of Directive 223 
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93/42/EEC on medical devices (“used specifically for diagnostic and/or therapeutic purposes”), 224 
has a demonstrated benefit over risk, and is CE-marked.43 In Germany, medical apps are 225 
classified as medical devices if they follow EU guidelines and the German Medical Devices Act 226 
and are CE-marked.44 The situation in the UK was previously similar but is currently in flux as 227 
the UK is imminently set to leave the EU.  228 
 229 
More recently, the European Commission has made considerable efforts to introduce and 230 
implement the MDR as a new regulatory framework, which will provide clarity on what is (and 231 
what is not) a medical device software.42  232 
 233 
b) Food and Drug Administration (FDA) 234 
With a view to prioritizing its resources in the face of an explosive growth of digital health apps, 235 
the FDA has attempted to draw a line between those that do and do not require regulation. In 236 
2015, it released a guidance document for mobile medical applications for apps that meet the 237 
definition of a device in section 201(h) of the Federal Food, Drug and Cosmetic Act (FDCA).32 238 
This definition covers apps intended to be used as accessories to regulated medical devices 239 
and those that are standalone software. However, the guidance expressed its intention to 240 
exercise “enforcement discretion” over those judged to pose a lower risk to users (e.g., apps 241 
that provide people with diabetes encouragement to meet their health goals or provide them 242 
with tools to track their health information). Thus, using this “risk-based” approach, mobile apps 243 
that calculate insulin doses are within the scope of regulation, while apps that simply organize 244 
and/or provide health or nutritional information are not. The FDA lists approved/cleared apps in 245 
its 510(k) and PMA databases and on its Registration & Listing Database.45 246 
 247 
These guidelines were updated when the US Congress passed the 2016 21st Century Cures 248 
Act, which specifically excludes from the definition of “medical device” certain low-risk medical 249 
software. Examples of exclusions from regulation as a medical device include software that 250 
supports administrative functions, encourages a healthy lifestyle, serves as an electronic patient 251 
record, assists in displaying or storing data, or provides limited clinical data support.46,47 By the 252 
end of 2019, the FDA will launch version 1.0 of the National Evaluation System for health 253 
Technology (NEST) initiative, which will be coordinated by the NEST Coordinating Center 254 
(NESTcc).48 NEST will improve access to evidence across the total product lifecycle of medical 255 
devices by strategically and systematically leveraging real-world evidence generated by 256 
participating institutions and applying advanced analytics tailored to the unique data needs and 257 
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innovation cycles of medical devices.49 Using a neural network data model that will represent 258 
nearly 500 million patient records from approximately 200 hospitals and 4000 outpatient clinics, 259 
this initiative seems promising for medical device stakeholders, especially if it will capture 260 
substantial data on people with diabetes. 261 
 262 
An important distinction is the difference in the regulation of mobile health apps from the 263 
regulation of digital therapeutics (sometimes referred to as “digiceuticals”). Digital therapeutics 264 
are clinically-validated digital, usually online, health technologies intended to treat a medical or 265 
psychological condition.50 These are governed by clinical data and regulatory approval as for 266 
drugs and medical devices. An example is Welldoc’s BlueStar Rx mobile app, which was 267 
cleared by the FDA as a prescription-only app to support the management of type 2 diabetes. 268 
An identical version without the bolus calculator was approved for direct sale without 269 
prescription (i.e., two versions are offered, allowing the company to offer the product through 270 
more channels). Both versions analyze diabetes data entered by the patient, comparing past 271 
data trends to form personalized guidance and creating a summary of curated data analytics to 272 
the health care team for clinical decision support, but the non-prescription version will not 273 
feature the insulin calculator that the full version does. As of October 2018, Welldoc is moving 274 
into Phase 2 for ongoing Quality Improvement research of BlueStar.51 In essence, digital 275 
therapeutics like BlueStar Rx focus on delivering clinical outcomes and are regulated by the 276 
FDA. On the other hand, mobile health apps, especially those that do not provide clinical 277 
recommendations, are largely not.  278 
 279 
Whether a mobile app has regulatory clearance/approval or not, we believe that all clinical 280 
performance claims made by “digital health technology” should be backed by clinical evidence 281 
and real-world performance/outcomes. Real-world data and real-world evidence have been 282 
increasingly recognized by regulatory bodies, including the FDA, to enhance clinical research 283 
and support regulatory decision making for drugs, biologics, and devices,52,53 and thus the same 284 
should be done for mobile apps. The FDA has published a Digital Health Innovation Action Plan 285 
that outlines a reimagined approach to foster digital health innovation while continuing to protect 286 
and promote public health.46 This effort includes three goals:  287 
(i) Providing guidance to provide clarity on the medical software provisions of the 21st 288 
Century Cures legislation;  289 
(ii) Launching an innovative pilot pre-certification program to develop a new approach to 290 
digital health technology oversight (FDA Pre-Cert for Software); and  291 
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(iii) Building expertise within the Agency (including recruitment of additional dedicated 292 
and specialized staff). 293 
 294 
In recent months, the FDA has further developed its digital health Software Precertification Pilot 295 
Program (Pre-Cert) with the goal of developing a more tailored pathway that enhances safety 296 
and effectiveness of such devices while supporting the innovation and availability of high-quality 297 
digital health tools. This program will allow the FDA to first look at the company, rather than 298 
primarily at the digital health software product being submitted, in order to expedite product 299 
reviews from vetted “excellent” companies.54 The components of the Pre-Cert program are:  300 
(i) Excellence appraisal and certification: Evaluating organizational excellence based on 301 
five criteria for quality and organizational excellence principles: 1) product quality, 2) 302 
patient safety, 3) clinical responsibility, 4) cybersecurity responsibility, and 5) 303 
proactive culture. 304 
(ii) Review determination: A risk-based framework for pre-certified organizations is to be 305 
established to determine the premarket review pathways for their products. 306 
Incorporating principles from the International Medical Device Regulators Forum 307 
(IMDRF)’s Software as a Medical Device (SaMD) (discussed in the next section), the 308 
final framework for each Software as a Medical Device (SaMD) will be based on the 309 
state of the health care condition addressed, the significance of the information 310 
provided to support health care decisions, and descriptions of the core functionality 311 
and device. 312 
(iii) Streamlined review: FDA review of the information received, which is made 313 
streamlined because (i) and (ii) provide information that does not need to be 314 
submitted again. 315 
(iv) Real-world performance: Post-launch product monitoring efforts on product-specific 316 
real-world performance analytics (RWPA). RWPA will consist of real-world health 317 
analytics (RWHA: human factors and usability engineering, clinical safety, and health 318 
benefits), user experience analytics (UXA: user satisfaction, engagement, feedback 319 
channels, and issue resolution), and product performance analytics (PPA: 320 
cybersecurity and product performance; data to be collected by the respective 321 
company).55  322 
 323 
The current pilot Pre-Cert program, which remains in a test plan phase, includes nine software 324 
companies (Apple, Fitbit, Johnson & Johnson, Pear Therapeutics, Phosphorus, Roche, 325 
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Samsung, Tidepool, and Verily), seven of whom have software relevant to diabetes. In 2019, 326 
FDA will test the effectiveness of the Pre-Cert program by reviewing a number of SaMD 327 
products under a traditional de novo pathway and, in parallel, a Pre-cert pathway to see if the 328 
Agency gets the same result.48 329 
 330 
Guidance from other bodies 331 
a) International Medical Device Regulators Forum (IMDRF) 332 
The IMDRF, founded in 2011, is a group of international medical device regulators whose goals 333 
are to build on the work of the Global Harmonization Task Force on Medical Devices (GHTF) 334 
and accelerate medical device regulatory harmonization and convergence.56 Members include 335 
officials from the FDA, European Commission, Australian Therapeutic Goods Administration, 336 
Chinese National Medical Product Association (NMPA), and Russian Federal Service for 337 
Surveillance in Healthcare (Roszdravnadzor).  338 
 339 
The group has released several influential documents. Among them is "Software as a Medical 340 
Device (SaMD): Possible Framework for Risk Categorization and Corresponding 341 
Considerations,” which was released in 2014 and introduces a foundational approach, 342 
harmonized vocabulary, and general and specific considerations for manufacturers, regulators, 343 
and consumers to consider in the context of SaMD.57 In 2015, the group published “Software as 344 
a Medical Device (SaMD): Application of Quality Management System” to help manufacturers 345 
and regulators attain a common understanding and vocabulary for the application of medical 346 
device quality management system requirements to SaMD.58 In 2017, IMDRF published 347 
“Software as a Medical Device: Clinical Evaluation” to provide guidance in gathering evidence 348 
for clinically meaningful SaMDs, elaborating on valid clinical association, analytical validation, 349 
and clinical validation.59 These efforts on the global harmonization of medical device regulatory 350 
processes, including those governing digital health technology, provide guiding principles as a 351 
template for other regulatory agencies to incorporate into their respective frameworks. 352 
 353 
b) World Health Organization (WHO) 354 
In 2018, WHO published “Classification of digital health interventions v1.0” with similar aims of 355 
providing governments, technologists, clinicians, researchers, and other communities in digital 356 
health a shared and standardized language in assessing digital health interventions. The 357 
document organizes digital health technologies into interventions for clients, HCPs, health 358 
system or resource managers, and data services. It also presents health system challenges and 359 
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digital health interventions to address them. For example, the challenge of HCPs losing clients 360 
to follow-up can be addressed by sending alerts and reminders; this intervention is categorized 361 
under “client communication systems.”60 WHO’s newly available resource provides several 362 
examples of current apps and their uses and, more importantly, a solid framework to underpin 363 
future developments in digital technology. 364 
 365 
c) Nationwide Health Care Service 366 
At least one nationwide health care service now provides a digital health apps certification 367 
program. The United Kingdom’s National Health Service (NHS) describes its process, which 368 
involves app providers to show evidence that their products pass tests in outcomes, clinical 369 
safety, data protection, security, usability and accessibility, interoperability, and technical 370 
stability.61 The NHS has so far listed 13 apps that are "safe and secure" for the management of 371 
diabetes: Changing Health, GDm-Health, Liva UK, Low Carb Program, mapmydiabetes, 372 
Mumoactive, My Diabetes My Way, My Health Fabric, my mhealth: myDiabetes, nujjer, 373 
OurPath, Oviva, and Sugarmedown.62 This is the only database dedicated solely to apps 374 
approved by a regulatory that we are aware of. 375 
 376 
Issues faced by the diabetes community  377 
Although the rapid growth of digital health apps potentially brings great benefit, still-early 378 
development of the field also raises questions and challenges: for example, how physicians and 379 
other HCPs can maintain an adequate understanding of commonly used apps in order to 380 
provide guidance to people with diabetes, and how data can be kept confidential and secure.  381 
Below we outline nine major issues that need to be addressed by regulatory authorities, 382 
policymakers, professional organizations, researchers, product manufacturers, and HCPs. 383 
 384 
1. Availability of evidence 385 
Although there are almost half a million mobile health apps available for download, there are far 386 
fewer randomized control trials (RCTs), case-control studies, and cohort studies that evaluate 387 
whether app-based interventions improve health-related behaviors. One of the reasons there 388 
are so few published RCTs of digital health is that a product is never “frozen” in time like a 389 
medication – an app usually is constantly learning and improving. Even a three-month RCT is 390 
likely to have at least a two-year timeline from conception to publication – a long period of time 391 
in a fast-developing space. What should also be kept in mind is that RCTs on digital health 392 
apps, are, by nature, never blinded, so a placebo effect cannot be ruled out. Another reason for 393 
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the relatively few RCTs is that the typically lower commercial value and shorter life cycles of 394 
these products does not support the high cost and time involved in conducting RTCs. As a 395 
result, developing apps to be used in medical studies may be a less attractive business model 396 
for mobile health app developers.  397 
 398 
In 2016, Zhao and others searched for peer-reviewed articles in English published from January 399 
2010 to June 2015 on app-based health interventions targeted at adult populations. While their 400 
initial search returned over 3300 articles, the exclusion of qualitative studies and those in which 401 
mobile apps were not the primary intervention tool resulted in a final 23 articles from which 402 
primary or secondary outcomes for analysis could be extracted.63 This small number starkly 403 
contrasts with the number of mobile health apps available for download. Of these 23 articles, 404 
only 10 described studies relevant to diabetes management. Four of these ten provided 405 
interventions intended to improve lifestyle (e.g., physical activity, weight control, and diet 406 
control), and three aimed to improve medication management. However, only two actually 407 
measured changes during a lifestyle intervention, and only one was specifically targeted at 408 
diabetes management. Several of the apps assessed in this study improved short-term 409 
adherence and enhanced intervention effectiveness, but many others yielded no effect. Zhao 410 
and others concluded that their results provided a snapshot of the current evidence of 411 
effectiveness for health-related apps, but large sample, high-quality, adequately powered RCTs 412 
are required. Similarly in 2016, Drincic and others reviewed mobile medical apps that were 413 
commercially available to people with diabetes in the US or EU. They found only 14 apps with 414 
clinical outcomes data published in peer-reviewed literature or have been cleared by the US 415 
FDA or received a CE mark in Europe. Drincic and others found these apps to positively affect 416 
outcomes, such as HbA1c, hypoglycemia incidence, and diabetes self-care measures, in the 417 
short term. However, more data and long-term studies are needed.31  418 
 419 
More recently, a 2018 comprehensive study for the US Agency for Healthcare Research and 420 
Quality found only 11 randomized clinical trials (RCTs) reporting health outcomes amongst the 421 
hundreds of commercially-available apps for diabetes self-management. Of these 11 RCTs, 422 
only five were associated with clinically significant but small improvements in HbA1c. None of 423 
the studies demonstrated improvements in quality of life, blood pressure, weight, or body mass 424 
index. Methodological issues included limited duration (2-12 months), potential confounding by 425 
other co-interventions, and inconsistency in the reporting of randomization, allocation, masking 426 
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of outcomes assessment, and method of analysis in relation to drop-outs. None of the studies 427 
were considered high quality.64  428 
 429 
Thus, while the available studies of app-based interventions show promise for promoting 430 
healthy behavior and managing complex diseases, such as diabetes, they are extremely limited 431 
in both quantity and quality. The studies previously mentioned in this section all report their 432 
respectively assessed apps to improve or have promise in improving short-term outcomes. 433 
However, all of these studies also conclude that more rigorous, larger sample, and longer-term 434 
RCTs are required to distinguish the effect of these apps from possible concomitant effects. In 435 
principle, well-designed studies with larger sample sizes and longer durations are needed to 436 
gather and assess evidence of sustainable effectiveness over time.  437 
 438 
2. Adequate information and training 439 
Beyond the field of diabetes, evidence-based apps are available as clinical decision-making 440 
tools for HCPs, with a scope that includes disease diagnosis, medical calculators, literature 441 
search, and reference drug information.65 With thousands of apps currently being developed 442 
and updated, issues arise. These issues include: how to keep HCPs up-to-date with the apps 443 
most appropriate to use, how to support people with diabetes to use these digital tools, and how 444 
to ensure that using them will result in benefit rather than harm. Although it is important for 445 
HCPs to stay up-to-date on the digital health app landscape, we acknowledge that it is 446 
unrealistic for HCPs to meet this expectation on top of their highly burdened workload. As a 447 
result, other stakeholders in the diabetes community should work with and alongside HCPs in 448 
addressing this issue.  449 
 450 
3. Accuracy, clinical validity, and quality 451 
Because the majority of mobile health apps are not subject to regulation, data for assessment of 452 
accuracy, hereby defined as the ability to correctly differentiate patient and healthy cases (the 453 
sum of true positive and true negative cases over the sum of all cases),66 often may not be 454 
available. Patient involvement and self-management are the key to diabetes care, but there is a 455 
fine line between empowerment and unregulated harm. For example, potentially questionable 456 
data and/or medical opinion from a mobile health app can place a burden on a consultation if 457 
the information provided does not align with clinical guidelines in disease management.67  458 
 459 
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A number of studies have evaluated the accuracy of mobile medical and health apps, though 460 
there are few studies that focus on diabetes health apps. Chavez and others analyzed the 89 461 
most popular free English-language diabetes apps by each app’s level of engagement, 462 
functionality, aesthetics, information, and number of diabetes-specific management tasks met. 463 
Using the Mobile App Rating Scale (MARS), they found that while this subset of mobile health 464 
apps ranked “acceptable-good” in engagement, functionality, and aesthetics, they ranked “poor-465 
acceptable” in information, app quality score, and app subjective score.68 Bierbrier and others 466 
evaluated the accuracy of 14 smartphone medical calculation apps aimed at internists, including 467 
those that calculated the severity or likelihood of liver disease or of having a pulmonary 468 
embolism. Of 1240 calculations run on these apps, 98.6% were accurate, with six of the 14 469 
functions assessed as 100% accurate. Although errors were overall few, some were clinically 470 
significant. The authors point out that in the absence of regulation, the responsibility for any 471 
adverse consequences of using these apps falls on the individual clinician.69  472 
 473 
Additionally, a 2018 study by Lum and others pointed out the need for quality assurance 474 
mechanisms for diabetes apps to support people with diabetes. Of the approximately 370 475 
diabetes apps that met the researchers’ criteria for blood glucose self-management (blood 476 
glucose level recording; goal setting for blood glucose levels and HbA1c; reminders, alerts, and 477 
action prompts; and patient education on hypoglycemia and hyperglycemia management), the 478 
majority did not provide real-time decision support or situation-specific education on blood 479 
glucose self-management. All of these apps recorded blood glucose levels. However, only 480 
about a third had goal setting and reminders to measure blood glucose and record HbA1c. 481 
Approximately a third of apps alerted users to hypoglycemia or hyperglycemia, and only ten 482 
percent of apps educated users on blood glucose management.70 483 
 484 
Thus, greater scrutiny is needed to oversee the accuracy, clinical validity, and quality of mobile 485 
health apps to protect patient safety. Apps that can be used by adolescents of parents for their 486 
children, as well as during pregnancy or old age, have to ensure that the advice given is suitable 487 
for this age-group. In addition, apps should clearly define the user group. 488 
 489 
Another factor that should be considered is the standardization of language and presentation 490 
(e.g., blood sugar, time in range, standard deviation, body mass index, etc.). Setting standards 491 
for how information is presented would lead to fewer errors in translation and interpretation from 492 
app to HCP to patient.  493 
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 494 
4. Technological issues 495 
Technological issues apply to diabetes digital health apps. These include the maintenance of 496 
mobile apps so that they are up-to-date with the latest technological platforms and operating 497 
systems and free of bugs that degrade app performance. App developers need to consider 498 
carefully battery usage, input/output ports (e.g., USB port, headphone jack, lightning port), and 499 
the impact of inconsistent illumination, mobile device cases, and inconsistent resolution with 500 
smartphone cameras.19 Additionally, the speed at which mobile app versions are released or 501 
new features are rolled out, as well as the tolerance level of acceptable error within a release, is 502 
far greater than those of medical technologies. From the user perspective, this provides greater 503 
medical choice in medical apps, but makes it more challenging to find and ensure acceptable 504 
performance among many apps of varying quality. 505 
 506 
5. Interoperability and Standardization  507 
Consumers use a variety of mobile technological platforms, including Android and Apple iOS. 508 
Android and Apple iOS are the dominant platforms in the US market, with a keyword search for 509 
“diabetes” performed in the Apple and Google Play stores in 2017 identifying 246 available apps 510 
for Android and 100 for Apple iOS.71 As of 2012, more than 75% of physicians in the US use 511 
Apple iOS devices.72 However, where these apps are available for less popular platforms, app 512 
developers should ensure they operate consistently to the same standard.  513 
 514 
It is also important that data recorded in health apps be easily transmitted from smartphones to 515 
other platforms, such as electronic health records for sharing with HCPs. An example Is Apple 516 
Health, which is a health informatics mobile app that functions as a central repository for health 517 
information. Apple’s Healthkit can be integrated into multiple mobile health and fitness apps on 518 
Apple products, and record and share health data.73 An example of an app integrated with 519 
Apple Health is Tidepool Mobile, which can connect to Apple Health and show data from users’ 520 
insulin pumps, CGM, and sources outside of Dexcom devices.74 Google Fit is an approximate 521 
equivalent to Apple Health for the Android platform.75 Advances in integration and automation of 522 
data collection have come far, and we anticipate these advances to continue and improve. 523 
 524 
6. Differences among populations 525 
In 2017, an estimated 12 million people ≥65 years of age and 193,000 people <20 years of age 526 
had diabetes in the US.76 The differences in these two populations are important because 527 
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younger populations (usually with type 1 diabetes) are typically more proficient at using 528 
smartphones than older populations. Consequently, apps targeted for older people with 529 
diabetes must be designed with their expected level of technology proficiency kept in mind. In 530 
addition, currently available diabetes management apps may not be available in languages 531 
other than English or accessible to people with certain physical or mental disabilities (e.g., color 532 
blindness, blindness, hearing impairment, etc.). Furthermore, those from remote regions and 533 
areas of extreme socioeconomic deprivation may not have access to smartphone technology. 534 
The cost of obtaining and activating a smartphone, not to mention the cost of apps that are not 535 
free of charge to download, may be a significant barrier on top of the premium prices paid for 536 
most branded diabetes drugs.72 537 
 538 
So far, app developers have made strides in increasing the durability of benefits by utilizing 539 
“gamification” to encourage long-term behavior changes and adherence to diabetes 540 
management principles. An example is a patient engagement program, in which “points” can be 541 
earned for time spent in range for blood glucose measurements and redeemed for pharmacy 542 
rebates, HCP visits, or other benefits. This approach can also be used to encourage health 543 
outcomes;77 examples exist within mySugr and Medtronic Inner Circle.78,79 Additionally, United 544 
Healthcare launched its Motion program, offering up to $4 per day for beneficiaries who meet 545 
activity goals.80 While gamification can certainly incentivize consumers to monitor their health 546 
better, it is not a one-size-fits-all solution. Such programs may have the drawback of leaving 547 
behind those who are in the most need of help, such as those experiencing socio-economic 548 
deprivation. Additionally, clear proof that gamification improves outcomes and results in long-549 
term changes in health is missing.81 550 
 551 
Another potential way to engage consumers, particularly those of older populations, is to involve 552 
Centers for Medicare & Medicaid Services (CMS) reimbursement. Reimbursement policies in 553 
the US could include, for example, sharing of health data in place of an office visit or sharing of 554 
CGM data. 555 
 556 
7. Appropriate role of health care professionals (HCPs) 557 
HCPs play an important role in advancing the use of diabetes mobile health apps. While a 558 
mobile health app cannot (and should not) replace a HCP, mobile health apps can certainly 559 
supplement and bolster medical practice.  560 
 561 
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As previously discussed, HCPs need to be supported to stay up-to-date on the diabetes digital 562 
app landscape. The ability to communicate regularly with people with diabetes and monitor their 563 
glycemic data gives health care professionals an unprecedented opportunity to monitor and 564 
improve quality of care and health outcomes (see Recommendations below).  565 
 566 
8. Role of professional organizations 567 
Professional organizations like ADA and EASD play an important role in shaping the future of 568 
health care. In addition to the above-mentioned efforts of the WHO and IMDRF to classify digital 569 
health technology, issues remain that professional organizations need to address. We believe 570 
the American Medical Association, the International Diabetes Federation, and many others can 571 
make a greater positive impact on patient populations worldwide in collaboration with WHO and 572 
IMDRF (see Recommendations below). 573 
 574 
9. Data security and privacy 575 
Data security is a key aspect in a digital world, especially for medical data. Although diabetes 576 
apps primarily permit people with diabetes to monitor their own data and discuss their data with 577 
health professionals, safety regarding data security and privacy remains a risk and 578 
cybersecurity has to be ensured.  579 
 580 
Users may believe that their health data stored in apps are private, but that is often not the 581 
case. A 2014 study of diabetes apps for Android smartphones demonstrated that diabetes apps 582 
routinely shared information with third parties.82 Because of the potential adverse impact of 583 
sharing sensitive health data, app developers should implement and fully disclose their privacy 584 
policies to users. App developers should also allow users to have full control over what data 585 
they are willing to share with third parties. Such cybersecurity measures must be implemented 586 
to protect privacy and enhance data security so that people with diabetes have adequate 587 
privacy protection and are not judged or discriminated based on their blood glucose levels, 588 
adherence to their care, or just their diabetes diagnosis.  589 
 590 
People with diabetes have a high need for secure information when viewing their glucose levels 591 
and insulin doses on wireless diabetes devices, such as blood glucose monitors, continuous 592 
glucose monitors, and insulin pumps.  Medical devices are prone to security breaching attacks; 593 
for example, incidents have been reported when data from insulin pumps were accessed 594 
remotely and their function controlled without knowledge of the user. Although there have been 595 
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no publicly reported incidents of users being harmed from hacking attacks, such situations have 596 
the potential to be life-threatening.83 Data stored in health data apps should be sufficiently 597 
encrypted to prevent serious and malicious attacks.  598 
 599 
An example that the cybersecurity regulation of diabetes mobile health apps could follow is the 600 
Diabetes Technology Society’s guidance on the “Standard for Wireless Diabetes Device 601 
Security (DTSec).” DTSec establishes a high level of assurance that electronic products deliver 602 
the security protections claimed by their developers and required by their users. A DTSec-603 
certified product must pass evaluation by a DTSec-approved lab and the DTSec Working Group 604 
(DWG) before it can be listed under a publicly disclosed DTSec evaluated products list.84  605 
 606 
Conclusions and Outlook  607 
Digital health technology, especially digital health apps, for people with or at risk for diabetes 608 
has developed at a rapid pace and become an increasingly common aspect of diabetes care 609 
and self-management in certain populations. However, several barriers remain that prevent 610 
digital health technology from reaching its full potential to improve diabetes therapies and the 611 
lives of people affected by diabetes.  612 
 613 
Insufficient evidence (at least from a conventional way of looking at evidence) of clinical validity, 614 
effectiveness, accuracy, and safety are some of the largest issues that limit the effectiveness of 615 
diabetes digital health technology. Furthermore, poor usability due to technological issues, 616 
interoperability issues, and differences among populations is another barrier. This web of 617 
interconnected issues cannot be solved by one party alone; rather, commitment from regulators, 618 
industry, clinical experts, and funding and patient organizations is needed for the necessary 619 
clinical evidence to be gathered.  620 
 621 
We outline a list of considerations for regulatory agencies, manufacturing companies, 622 
international and national professional societies, funding bodies, researchers, HCPs, and 623 
people with diabetes to take into careful consideration. These can be categorized into the 624 
following themes: 625 
• More systematic and structured guidelines for digital health app development and 626 
assessment [1a-c, 3d-e], 627 
• Improved consistency and accessibility of safety reports and app documentation [2a-b, 628 
2d], 629 
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• Greater investment in gathering of clinical data to provide evidence on digital health 630 
interventions [4a-b, 5a-b], 631 
• Increased accessibility for all consumer populations to use diabetes mobile apps 632 
confidentially and securely [2c, 2g, 3c], and 633 
• Increased communication and cooperation across stakeholder groups [1d-g, 2e-f, 3a-b, 634 
3f, 6a-c, 7a-c]. 635 
 636 
Today’s world of products and services, including digital health apps, is moving towards a 637 
market of integration. Apps are converging towards a data-capturing and auto-analyzed future 638 
with algorithm-based recommendations for users affecting their behavior and decisions. We 639 
envision an ongoing role of EASD, ADA, and other professional medical associations in 640 
supporting and expanding the field of diabetes digital health technology in the march to 641 
integration and continued automation. We call upon regulatory agencies and manufacturing 642 
companies to work urgently and collaboratively with health professionals, researchers, and 643 
people with diabetes to create an environment in which diabetes can be managed safely and 644 
effectively, bringing benefits to all stakeholders and the entire diabetes community.  645 
  646 
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Consensus Report Recommendations 647 
1. Regulatory agencies should: 648 
a. establish and update standards to be met by digital health technology 649 
developers at premarketing and postmarketing stages, such as elements of 650 
clinically validated information (not necessarily from RCTs), service systems 651 
to support users, effectiveness parameters to enhance outcomes, and 652 
functions to transmit data to other devices, while also supporting the 653 
innovation of the market 654 
b. provide a regulatory paradigm, such as that outlined by IMDRF, which is 655 
tailored specifically to software, taking the short product life cycle and rapid 656 
turnover of updates into account 657 
c. provide guidance for obtaining and promoting evidence of safety, 658 
effectiveness, and other performance measures 659 
d. find ways to evaluate digital health apps’ security, accuracy, and reliability 660 
(e.g., by recognizing and following the DTSec model), including supporting 661 
companies (often small) to generate real world data when they have a 662 
product that has achieved a certain standard 663 
e. provide, publicize, and maintain a single publicly accessible international 664 
database of available digital health apps and their utility/quality, including 665 
harmonizing on the parameters that would measure utility/quality and how 666 
these parameters would be assessed85  667 
f. publish an annual summary of regulatory activities  668 
g. work to harmonize their activities 669 
2. Manufacturing companies should: 670 
a. comply with regulations, industry standards, and best practices established 671 
for digital health app development and marketing, such as providing a 672 
regularly updated flow chart that describes the decision-making process for 673 
releasing app updates; a broader plan for software maintenance and testing; 674 
and plans for obsolescence in a specific mobile device model or operating 675 
system for which the app has been validated is ceased16  676 
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b. include sufficient documentation, training modules, and help-desk resources 677 
to ensure optimal use 678 
c. provide interfaces that are user-friendly across all demographic groups and 679 
can be personalized with real-time insights and suggestions for individual 680 
users (taking their socioeconomic status into account, especially around 681 
health literacy) 682 
d. report all safety-related data promptly and transparently to the regulatory 683 
authorities  684 
e. cooperate with academic and health care professionals to provide balanced 685 
and adequate information for people with diabetes and package the output 686 
data in standardized formats for ease of access in electronic health records  687 
f. enable users to opt to submit their data anonymously to track outcomes and 688 
demographics following a crowd-sourcing model 689 
g. incorporate high degrees of data security and patient confidentiality (e.g., by 690 
adhering to the DTSec model) 691 
3. International and national professional societies should: 692 
a. bring people with diabetes, health care professionals, manufacturing 693 
companies, and regulatory authorities together to facilitate digital health 694 
technology interventions  695 
b. encourage academia and medical associations to advance research in digital 696 
health app effectiveness, safety, and outcomes  697 
c. help set expectations for HCPs and consumers of the strengths and 698 
limitations of digital technology 699 
d. provide evidence-based guidelines on the effectiveness of digital health 700 
interventions 701 
e. recommend appropriate forms of structured education required for HCP to 702 
support people with diabetes to benefit from the best digital health (HCPs 703 
cannot be trained in the use of each app; however, they can be supported in 704 
maintaining a basic understanding of what apps can do and how they are 705 
used) 706 
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f. maintain a list of endorsed apps that have passed a threshold of accuracy, 707 
dependability, and ease of use for both people with diabetes and HCPs 708 
4. International and national research funding bodies should: 709 
a. provide or facilitate funding for well-designed independent clinical evidence 710 
that measure safety, effectiveness, outcomes, and use in real-world settings 711 
b. provide or facilitate significant financial support for long-term data collection  712 
5. Researchers/academics should: 713 
a. openly report and share the patient-level results of all clinical evidence 714 
b. develop and validate specific and appropriate patient-related outcome 715 
measures  716 
6. Health care professionals should: 717 
a. be knowledgeable of digital health apps and their strengths and weaknesses 718 
b. support and inform people with diabetes on the use of digital health apps to 719 
augment diabetes management and lifestyle modification 720 
c. utilize health data to improve quality of care and health outcomes  721 
7. Consumers of digital health apps–people with diabetes, family members, 722 
caregivers–should: 723 
a. consider digital health apps as a valuable addition or supplement to disease 724 
management or prevention 725 
b. discuss with their health care professionals available and appropriate digital 726 
health app options, as well as advice or counseling received from the app that 727 
affects behavior or care decisions  728 
c. submit app reviews, which would include information on digital health app 729 
efficacy, success, errors, and malfunctions, as well as report apps that appear 730 
to be unsafe or illegally marketed, to the manufacturers and appropriate 731 
regulatory agencies and care organizations (e.g., ADA) 732 
  733 
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